Ron de Jong

2.3k total citations
33 papers, 1.6k citations indexed

About

Ron de Jong is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Ron de Jong has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Hematology. Recurrent topics in Ron de Jong's work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Ron de Jong is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Ron de Jong collaborates with scholars based in United States, Japan and Netherlands. Ron de Jong's co-authors include Nora Heisterkamp, John Groffen, Johanna ten Hoeve, Morris J. Birnbaum, Tilman Oltersdorf, Argiris Efstratiadis, Mark S. Forman, Thomas Ludwig, Diana W. Shineman and Matthias Szabolcs and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ron de Jong

30 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron de Jong United States 19 1.1k 289 224 179 164 33 1.6k
Jeffrey H. Till United States 11 1.3k 1.2× 431 1.5× 250 1.1× 173 1.0× 205 1.3× 12 1.9k
Daniela Barilá Italy 26 1.4k 1.3× 472 1.6× 239 1.1× 239 1.3× 152 0.9× 50 1.9k
Linda S. Mulcahy United States 11 1.1k 1.0× 492 1.7× 256 1.1× 225 1.3× 73 0.4× 13 1.7k
T. INAZU Japan 18 841 0.8× 193 0.7× 169 0.8× 826 4.6× 186 1.1× 50 1.7k
Jin‐Chen Yu China 14 1.7k 1.6× 426 1.5× 436 1.9× 324 1.8× 260 1.6× 39 2.5k
Tim P. Green United Kingdom 13 699 0.7× 504 1.7× 118 0.5× 59 0.3× 71 0.4× 14 1.2k
Valerie L. Goss United States 11 1.7k 1.6× 260 0.9× 338 1.5× 142 0.8× 264 1.6× 15 2.2k
Bruce W. Konicek United States 20 1.8k 1.7× 447 1.5× 80 0.4× 234 1.3× 178 1.1× 37 2.3k
Bertrand Leblond France 17 665 0.6× 142 0.5× 121 0.5× 101 0.6× 51 0.3× 29 1.2k
Da-Sheng Wang United States 12 696 0.7× 133 0.5× 112 0.5× 181 1.0× 195 1.2× 13 1.1k

Countries citing papers authored by Ron de Jong

Since Specialization
Citations

This map shows the geographic impact of Ron de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron de Jong more than expected).

Fields of papers citing papers by Ron de Jong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron de Jong. The network helps show where Ron de Jong may publish in the future.

Co-authorship network of co-authors of Ron de Jong

This figure shows the co-authorship network connecting the top 25 collaborators of Ron de Jong. A scholar is included among the top collaborators of Ron de Jong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron de Jong. Ron de Jong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grimshaw, Charles E., et al.. (2020). Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times. SLAS DISCOVERY. 26(5). 676–683.
2.
Mikami, Satoshi, et al.. (2019). Rational discovery of a highly novel and selective mTOR inhibitor. Bioorganic & Medicinal Chemistry Letters. 29(21). 126659–126659. 3 indexed citations
3.
Riopel, Matthew, Jong Bae Seo, Gautam Bandyopadhyay, et al.. (2018). Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function. Journal of Clinical Investigation. 128(4). 1458–1470. 30 indexed citations
4.
Riopel, Matthew, Melanie Vassallo, Erik Ehinger, et al.. (2018). CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice. Molecular Metabolism. 20. 89–101. 25 indexed citations
5.
Balakrishna, Deepika, Shweta Pandya, Mark S. Hixon, et al.. (2017). MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Molecular Cancer Therapeutics. 16(7). 1269–1278. 11 indexed citations
6.
Shi, Lihong, Deepika Balakrishna, Takashi Hoshino, et al.. (2013). Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor. Molecular Cancer Therapeutics. 12(4). 460–470. 34 indexed citations
7.
Gangloff, Anthony R., Jason W. Brown, Ron de Jong, et al.. (2013). Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(16). 4501–4505. 28 indexed citations
8.
Griffin, Patrick R., Steffan T. Nawrocki, Takashi Satou, et al.. (2011). The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies. Blood. 118(21). 581–581.
9.
Bressi, Jerome C., Ron de Jong, Yiqin Wu, et al.. (2010). Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity. Bioorganic & Medicinal Chemistry Letters. 20(10). 3138–3141. 47 indexed citations
10.
Liu, Xuesong, Yan Shi, Morris J. Birnbaum, et al.. (2006). Quantitative Analysis of Anti-apoptotic Function of Akt in Akt1 and Akt2 Double Knock-out Mouse Embryonic Fibroblast Cells under Normal and Stressed Conditions. Journal of Biological Chemistry. 281(42). 31380–31388. 31 indexed citations
11.
Zhu, Gui‐Dong, Viraj B. Gandhi, Jianchun Gong, et al.. (2006). Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorganic & Medicinal Chemistry Letters. 16(13). 3424–3429. 42 indexed citations
12.
Easton, Rachael, Han Cho, Kristin Roovers, et al.. (2005). Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size. Molecular and Cellular Biology. 25(5). 1869–1878. 473 indexed citations
13.
Hemmeryckx, Bianca, Anja Reichert, Vesa Kaartinen, et al.. (2002). BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Oncogene. 21(20). 3225–3231. 23 indexed citations
14.
Hemmeryckx, Bianca, A. Reichert, Vesa Kaartinen, et al.. (2001). Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.. PubMed. 61(4). 1398–405. 38 indexed citations
15.
Jong, Ron de, et al.. (1998). C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells. Oncogene. 17(21). 2805–2810. 29 indexed citations
16.
Jong, Ron de, Johanna ten Hoeve, Nora Heisterkamp, & John Groffen. (1997). Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene. 14(5). 507–513. 75 indexed citations
17.
Salgia, Ravi, N. Uemura, Keiko Okuda, et al.. (1995). CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells. Journal of Biological Chemistry. 270(49). 29145–29150. 113 indexed citations
18.
Jong, Ron de, et al.. (1993). DNA-binding specificity of the S8 homeodomain. Nucleic Acids Research. 21(20). 4711–4720. 48 indexed citations
19.
Jong, Ron de & Frits Meijlink. (1993). The Homeobox Gene S8: Mesoderm-Specific Expression in Presomite Embryos and in Cells Cultured in Vitro and Modulation in Differentiating Pluripotent Cells. Developmental Biology. 157(1). 133–146. 36 indexed citations
20.
Jong, Ron de, et al.. (1992). DNA-binding activity of the murine homeodomain protein Hox-2.3 produced by a hybrid phage T7/vaccinia virus system. Gene. 116(2). 195–203. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey H. Till Breakdown of academic impact, for papers by Daniela Barilá Breakdown of academic impact, for papers by Linda S. Mulcahy Breakdown of academic impact, for papers by T. INAZU Breakdown of academic impact, for papers by Jin‐Chen Yu Breakdown of academic impact, for papers by Tim P. Green Breakdown of academic impact, for papers by Valerie L. Goss Breakdown of academic impact, for papers by Bruce W. Konicek Breakdown of academic impact, for papers by Bertrand Leblond Breakdown of academic impact, for papers by Da-Sheng Wang
Rankless by CCL
2026